Results 181 to 190 of about 112,243 (300)

Pharmacologic profiling of phosphoinositide 3-kinase inhibitors as mitigators of ionizing radiation-induced cell death. [PDF]

J Pharmacol Exp Ther, 2013
Lazo JS, Sharlow ER, Epperly MW, Lira A, Leimgruber S, Skoda EM, Wipf P, Greenberger JS.   +7 more
europepmc   +1 more source

Second‐generation prokineticin PKR1 receptor agonists: Advancing cardioprotection against chemotherapy‐induced toxicity

British Journal of Pharmacology, EarlyView.
IS39, a novel non‐peptide PKR1 agonist, confers cardioprotection against doxorubicin‐induced toxicity. IS39 activates PKR1‐mediated pro‐survival signalling in cardiomyocytes, reducing reactive oxygen species (ROS), DNA damage and fibrosis markers. In vivo, IS39 preserves cardiac geometry and function in mice exposed to chronic doxorubicin challenge ...
Anais Audebrand, Simone Brogi, Mustafa Tezeren, Andrea Tafi, Omer H. Ocak, Hasan Koyuncu, Igor Tetko, Laurent Désaubry, Canan G. Nebigil   +8 more
wiley   +1 more source

Targeting Inflammation and Immune Regulation in Chronic Inflammation Associated Cancers

Cancer Science, EarlyView.
Chronic inflammation sustains activation of key inflammatory pathways, including Nuclear factor kappa B (NF‐κB), Interleukin‐6‐signal transducer and activator of transcription 3 (IL6‐STAT3), Phosphoinositide 3‐kinase/Akt (PI3K/Akt), and Wingless/β‐catenin (Wnt/β‐catenin) signaling. This promotes immune dysregulation through the expansion and functional
Lawan Rabiu, Mengzhu Chinn, Feng Chen, Yerkezhan Yerkinkazhina, Yuan Tian, Wei‐Guo Zhu   +5 more
wiley   +1 more source

Transcriptional Reinforcement of the HER2–RAS Network in HER2‐Positive Gastric Cancer: The RUNX–SOS1 Axis in Context

Cancer Science, EarlyView.
RUNX‐dependent transcriptional control of SOS1 reinforces HER2–RAS signaling and may attenuate responses to HER2‐targeted therapies in HER2‐positive gastric cancer. ABSTRACT HER2‐positive gastric cancer represents a distinct molecular subtype characterized by chromosomal instability, variable HER2 amplification, and substantial intratumoral ...
Tatsuya Masuda, Takayoshi Watanabe, Toshinori Ozaki, Yasuhiko Kamikubo   +3 more
wiley   +1 more source

p75NTR Promotes Circadian‐Driven Mineralization During Tooth Development via CK2/PER2 Pathway

Cell Proliferation, EarlyView.
The diagram illustrates how the circadian rhythm regulates the p75NTR‐CK2‐PER2 axis, driving rhythmic biomineralisation during tooth development. ABSTRACT Circadian rhythm is an essential biological process that synchronises physiological activities with environmental light/dark cycles.
Manzhu Zhao, Hongyan Yuan, Di Wang, Meng Li, Bo Xie, Xuqiang Zou, Mingjie Lu, Ye Qiu, Jinlin Song   +8 more
wiley   +1 more source

Roles of ADP-Ribosyltransferases in Cancer. [PDF]

Oncol Res
Veilleux M, Nguyen A, Cao C, Shi Y.
europepmc   +1 more source

ITGA5 as a Dual Regulator of Epithelial‐Mesenchymal Transition and Epithelial Cell Anoikis Resistance: Functional Validation and Drug Prediction

Cell Proliferation, EarlyView.
Proteomics and functional validation reveal ITGA5 as a dual promoter of epithelial‐mesenchymal transition and anoikis resistance in human bronchial epithelium: targeting ITGA5 represents a novel therapeutic strategy for asthma airway remodelling. ABSTRACT Airway remodelling is a major contributor to persistent airflow limitation and irreversible lung ...
Ting Wang, Ling Rao, Xiaofang Li, Miaofen Zhang, Huiting Huang, Zhiyan Luo, Gang Liao, Yong Jiang, Shaofeng Zhan, Qiong Liu, Xiufang Huang   +10 more
wiley   +1 more source

Phosphoinositide-dependent kinase 1 (PDK1) in cancer: molecular insights and therapeutic strategies. [PDF]

Front Chem
Algheribe S, Zagzoog A, Boudjelal M, Islam I.   +3 more
europepmc   +1 more source

Acalabrutinib in Chronic Lymphocytic Leukemia: Pharmacology and Emerging Clinical Perspectives

European Journal of Haematology, EarlyView.
ABSTRACT Acalabrutinib, a second‐generation Bruton's tyrosine kinase inhibitor (BTKi), is characterized by enhanced specificity and selectivity for BTK with minimal off‐target effects, offering a significant evolution in the treatment of chronic lymphocytic leukemia (CLL). Its mechanism of action, a covalent binding to Cys481 within the BTK active site,
Gianluca Gaidano, Romano Danesi
wiley   +1 more source

Disrupting resistance: novel therapeutic approaches to combat multidrug resistance in fusion-negative rhabdomyosarcoma. [PDF]

Cancer Drug Resist
Codenotti S, Marampon F, Megiorni F, Cattaneo CG, Gastaldello S, Pozzo E, Sampaolesi M, Rota R, Keller C, Fanzani A.   +9 more
europepmc   +1 more source